Aimmune Therapeutics
8000 Marina Boulevard
Suite 300
Brisbane
California
94005-1884
United States
Tel: 650-614-5220
Fax: 650-616-0075
Website: http://www.aimmune.com/
Email: careers@aimmune.com
About Aimmune Therapeutics
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. Aimmune’s first investigational product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients.
134 articles with Aimmune Therapeutics
-
Aimmune Announces U.S. FDA Advisory Committee Meeting Date for AR101 for Peanut Allergy
5/16/2019
Company Enters into Commercial Supply Agreement for AR101
-
Aimmune Therapeutics Announces First Quarter 2019 Financial Results and Provides Operational Highlights
5/8/2019
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter ended March 31, 2019
-
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights
5/1/2019
Aimmune Therapeutics, Inc. announced that it will host a conference call on Wednesday, May 8, 2019, at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2019, and recent operational highlights.
-
With the ever-rising concerns over the costs of various prescription medications, a report from consumer pharmaceutical watchdog group Institute for Clinical and Economic Review released a report questioning the potential pricing of two yet-to-be-approved peanut allergy treatments.
-
Aimmune Therapeutics to Present at 18th Annual Needham & Company Healthcare Conference
4/3/2019
Aimmune Therapeutics, Inc. announced that Jayson Dallas, M.D., President and Chief Executive Officer, will present at the Needham & Company 18th Annual Healthcare Conference on Wednesday, April 10, 2019, at 8:00 a.m. Eastern Time in New York City.
-
European Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary Endpoint
3/25/2019
Aimmune Therapeutics, Inc. announced that its phase 3 European clinical trial of AR101 for the treatment of peanut allergy, known as ARTEMIS, met its primary efficacy endpoint.
-
When it comes to biotech and pharma innovation few places stand out like the Biotech Bay. The area is home to a plethora of innovative companies that are shaping the future of medical treatment for a variety of diseases and conditions on a daily basis.
-
Brisbane, Calif.-based Aimmune Therapeutics announced that its Phase III European clinical trial of AR101 for treatment of peanut allergy met its primary efficacy endpoint.
-
A new market research report by Clarivate Analytics, “Cortellis Drugs to Watch,” identified seven new drugs it believes will hit sales of $1 billion or more, the so-called “blockbuster” mark, by 2023.
-
U.S. FDA Accepts BLA Filing of Aimmune Therapeutics’ AR101 for Peanut Allergy
3/18/2019
Aimmune Therapeutics, Inc. announced that the Biologics License Application (BLA) for AR101 has been accepted for review by the U.S. Food and Drug Administration (FDA).
-
Aimmune Therapeutics to Participate in Three Investor Conferences in March
3/5/2019
Aimmune Therapeutics, Inc. announced that members of the Aimmune executive management team will participate in three upcoming investor conferences in March
-
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Recent Operational Highlights
2/28/2019
Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for life-threatening food allergies, announced financial results for the fourth quarter and full year 2018.
-
Evaluate recently published the Vantage Pharma, Biotech and Medtech 2018 in review report. The annual report offers insights into the previous year’s activities in biopharma and the medical device industry.
-
Aimmune Therapeutics Presents New AR101 Data at AAAAI, Including Demonstrated Reduction in Accidental Exposures to Peanut Requiring Treatment
2/25/2019
AR101 Associated with 70% Reduction in Allergic Reactions Due to Accidental Exposures That Required Treatment Compared to Placebo After Dose Escalation in PALISADE
-
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights
2/21/2019
Aimmune Therapeutics, Inc. announced that it will host a conference call on Thursday, February 28, 2019, at 5:00 p.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2018, and recent operational highlights.
-
Aimmune Therapeutics to Present AR101, OIT and Peanut Allergy Data at 2019 AAAAI Annual Meeting
2/4/2019
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data on AR101, oral immunotherapy, and peanut allergy at the 2019 American Academy of Asthma, Allergy and Immunology (AAAAI) Annual Meeting, taking place February 22–25 in San Francisco.
-
Aimmune Therapeutics Appoints Andrew Oxtoby as Chief Commercial Officer
1/18/2019
Proven Pharmaceutical Leader Brings Deep, Global Experience with Successful Product Launches, Commercialization and Strategic Planning
-
The partial government shutdown has entered day 24 and the pharma and medtech industry is beginning to feel the impact even more, particularly as the U.S. Food and Drug Administration grows more incapable of reviewing some medications for approval.
-
Aimmune Therapeutics and KKR Enter into $170M Loan Agreement to Fund AR101 Commercialization and Pipeline Advancement
1/4/2019
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has entered into a $170 million loan agreement with an affiliate of KKR, a leading global investment firm
-
Aimmune Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7th
1/2/2019
Aimmune Therapeutics (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CEO Jayson Dallas, M.D., will present a company overview at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 7, 2019, at 3:00 p.m. Pacific Time.